ESMO WCGIC 2021 | Tislelizumab in patients with unresectable HCC demonstrates durable responses

Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a Phase II global study of tislelizumab, an investigational PD1 antibody in patients with unresectable hepatocellular carcinoma (HCC). Tislelizumab demonstrated durable responses and was well tolerated in patients with previously systemically treated unresectable HCC, a patient population with a continued high unmet medical need. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.